Skip to main content

Breadcrumb

  1. Home

Home Care

Functional Communication Measure: Writing

  • Number of stroke patients who make progress as defined by an increase of one or more levels on the Writing Functional Communication Measure (FCM).

    CBE ID
    0442

Functional Communicaton Measure: Attention

  • This measure describes the change in functional communication status subsequent to speech-language pathology treatment of patients who have attention deficits.

    CBE ID
    0449

Functional Communicaton Measure: Reading

  • This measure describes the change in functional communication status subsequent to speech-language pathology treatment of patients with reading disorders.

    CBE ID
    0446

Functional Communicaton Measure: Swallowing

  • This measure describes the change in functional communication status subsequent to speech-language pathology treatment of patients who exhibit difficuty in swallowing.

    CBE ID
    0443

Functional status change for patients with Shoulder impairments

  • A self-report outcome measure of change in functional status for patients 14 years+ with shoulder impairments. The change in functional status assess using FOTO’s (shoulder) PROM is adjusted to patient characteristics known to be associated with functional status outcomes (risk adjusted) and used as a performance measure at the patient level, at the individual clinician, and at the clinic level to assess quality.

    CBE ID
    0426

Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)

  • Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB or ARNI therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge

    CBE ID
    0081

Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)

  • Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB or ARNI therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge

    CBE ID
    0081e